Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
A combination of hormonal therapy and chemotherapy (diethyl-estilbestrol or orchiectomy plus cyclophosphamide) was administered to 14 patients with histologic proof of untreated stage D prostatic adenocarcinoma with poor prognosis. Objective responses were obtained in 11 out of the 14 patients (78%), two of which were considered as complete regressions (14%). Response duration lasted for a mean of 9.5 months and the survival reached a mean of 14 months. The authors feel that is worth-while to treat very advanced cases of prostatic carcinoma with hormonal therapy and chemotherapy association.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004054:Diethylstilbestrol / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004054:Diethylstilbestrol; D003520:Cyclophosphamide